Leflunomide for Musculoskeletal GVHD After Allogeneic Stem Cell Transplant

GVHD, Chronic Clinical Trial

Official title:

Pilot Study of Leflunomide as First Line Therapy for Musculoskeletal GVHD

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04932564
• Other study ID #: 900643
• Secondary ID: CTRI/2021/04/033
• Status: Recruiting
• Phase: Phase 2
• Start date: June 15, 2021
• Est. completion date: April 9, 2023

Study information

• Verified date: June 2021
• Source: Tata Memorial Centre
• Contact: Sachin Punatar, MD, DM
• Phone: 02227405000
• Email: drsachin_punatar[@]yahoo.in
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Graft versus host disease (GVHD) is a well-known complication of allogeneic transplant. In GVHD, the cells of the donor attack the patient's tissues and cause damage. It can affect any organ or system of the body. In a proportion of patients, it affects the joints and muscles. This is known as musculoskeletal GVHD. The standard treatment of musculoskeletal GVHD is steroids. However, these are usually needed for prolonged periods, and cause a large number of additional problems in transplant patients.

Leflunomide is a drug which has been used for several years in diseases like rheumatoid arthritis (RA). RA is an auto-immune disorder. The biological mechanisms underlying RA and musculoskeletal GVHD are quite similar. Hence it is likely that leflunomide may work in musculoskeletal GVHD also. The investigator have previously used leflunomide in a few patients with musculoskeletal GVHD and have found it to be extremely effective. Also, it was very safe (unlike steroids). Yet another advantage is that it is fairly cheap.

The purpose of the current study is to study the efficacy and safety of leflunomide in patients with musculoskeletal GVHD in a prospective way.

Description:

The curative potential of allogeneic hematopoietic stem cell transplantation (allo-HCT) is hampered by acute and chronic graft-versus-host disease (GVHD). Although chronic GVHD (cGVHD) can affect any organ / system in the body, commonly affected are skin, oral cavity, eyes, liver, joints and fascia, and lungs. Involvement of these can occur alone or concurrently, and these lead to a significant negative impact on the patient's quality of life. Musculoskeletal involvement in chronic GVHD (mGVHD) can have varied presentations like fasciitis, myositis, arthritis, etc. The basic pathogenesis of mGvHD closely mimics autoimmune disorders like rheumatoid arthritis, systemic sclerosis, systemic lupus, etc.

The treatment goals of mGvHD include improvement or stabilisation of manifestations, limitation of long-term treatment related toxicities, improvement in functional capacity and quality of life. Corticosteroids, the standard frontline treatment, are typically administered for a median of 2 to 3years, leading to substantial morbidity. An effort to decrease corticosteroid doses has led to their use in combination with other drugs, such as cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, rituximab, etanercept, ruxolotinib, imatinib, ibrutinib, ECP (extra corporeal photopheresis), methotrexate etc, in frontline or second-line settings. All these drugs have been used with far and few responses but with significant treatment related toxicity and costs. As far as musculoskeletal GVHD is concerned, the British guidelines recommend corticosteroids as first line treatment and rituximab as second line option. However, the morbidity associated with long term steroid use warrants a quest for use of non-steroid therapies to be used in 1st line setting for chronic GVHD.

Leflunomide has been used in rheumatoid arthritis. At our centre, the investigator have previously used leflunomide for patients with musculoskeletal GVHD and found it to be effective and safe. Leflunomide is relatively cheap and potentially more effective compared to other more expensive alternatives. If proven to be effective in a larger cohort of patients, this drug could become the standard first line agent in this setting.

With this, the investigator have planned to carry out this study to assess the efficacy of leflunomide in musculoskeletal GVHD post allogeneic stem cell transplant.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: April 9, 2023
• Est. primary completion date: April 9, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 65 Years

Eligibility

Inclusion Criteria:

1. Willing to give written informed consent

2. Patients diagnosed with musculoskeletal mGvHD based on 2014 NIH consensus criteria (with diagnosis confirmed by biopsy only if clinically required).

3. Willing and able to comply with all study requirements, including treatment, and periodic assessments.

Exclusion Criteria:

1. Patients with known hypersensitivity to leflunomide especially previous Steven Johnson syndrome, toxic epidermal necrolysis after leflunomide.

2. Pregnant females

3. Patients with musculoskeletal manifestations explained by other potential causes ( (drugs, trauma, etc).

4. Patients with calculated glomerular filtration rate (GFR) <30ml/min at the time of screening.

Related Conditions & MeSH terms

• GVHD, Chronic
• Musculoskeletal Disease Other
• Musculoskeletal Diseases

Intervention

Drug:
• Leflunomide tablet
Leflunomide will be given at standard dose (100 mg OD x 3 days followed by 20 mg OD) in adults and weight based dose in children. The dosing for children will be as follows: <20 kg - 100 mg x 1 day followed by 10 mg every alternate day 20-40 kg - 100 mg x 2 days, followed by 10 mg daily >40 kg - Usual adult dose. This is scheduled to be continued for 1 year from the time of attaining complete response of musculoskeletal GVHD.

Locations

Country	Name	City	State
India	Tata Memorial Centre, Advanced Centre for Treatment, Research and Education in Cancer	Navi Mumbai	Maharashtra

Sponsors (1)

Lead Sponsor	Collaborator
Tata Memorial Centre

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall objective response rate	Response will be defined as per the NIH 2014 consensus response criteria working group for mGvHD.	Through study completion, an average of 2 years
Secondary	Time to response	The time required to achieve complete or partial response after treatment.	From date of start of leflunomide to date of first documented response, assessed up to 2 Years
Secondary	Time to best response	Time to best response will be recorded.	From date of start of leflunomide to date of documented best response, assessed up to 2 Years
Secondary	Duration of response	The duration of response will be calculated from the time of onset of objective response after initiation of treatment with leflunomide until the end of the follow-up, GVHD relapse, the development of new or the deterioration of pre-existing mGVHD symptoms, or the reinstitution of any additional agents to control the disease.	From date of first documented response to date of first documented progression or relapse, assessed up to 2 years
Secondary	Relapse rate	Relapse rate of mGVHD after stopping leflunomide will be recorded.	Through study completion, an average of 2 years